{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T19:19:05Z","timestamp":1791919145737,"version":"4.3.4"},"reference-count":58,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:00:00Z","timestamp":1788048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"\u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy, Timi\u0219oara, Romania"},{"id":[{"id":"https:\/\/ror.org\/00afdp487","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Antibody\u2013drug conjugates (ADCs) have become a major therapeutic platform in breast cancer and other solid tumors. Trastuzumab deruxtecan (T-DXd), trastuzumab emtansine (T-DM1), and sacituzumab govitecan (SG) differ substantially in antibody target, linker, payload, drug-to-antibody ratio, and bystander effect, resulting in heterogeneous pulmonary and cardiac toxicity profiles. This narrative review critically compares interstitial lung disease (ILD)\/pneumonitis and cardiotoxicity associated with these three agents, aiming to prevent inappropriate extrapolation of toxicity algorithms and to provide a practical, agent-specific framework for multidisciplinary care. Materials and Methods: A targeted narrative search of PubMed\/MEDLINE, Google Scholar, ClinicalTrials.gov, regulatory product information, and oncology\/cardio-oncology guidance was performed and updated on 24 August 2026. Priority was given to regulatory documents, pivotal trials, pooled safety analyses, real-world cohorts, systematic reviews, and multidisciplinary recommendations. Pharmacovigilance data and case reports were included only to characterize rare events. Results: T-DXd is associated with a clinically important ILD\/pneumonitis risk (approximately 12\u201315% in pooled analyses), predominantly grade 1\u20132 but occasionally fatal, requiring proactive surveillance, immediate interruption for suspected disease, and grade-directed corticosteroid therapy. T-DM1 shows a low but established pneumonitis incidence of approximately 1%, with permanent discontinuation recommended upon diagnosis. SG-related pneumonitis is rare and incompletely defined, without a T-DXd-like surveillance mandate. Both T-DM1 and T-DXd retain trastuzumab-derived cardiac monitoring requirements; symptomatic heart failure remains uncommon, although protocol-defined LVEF declines appear more frequent with T-DXd. SG lacks an established cardiomyopathy signal. Conclusions: Cardiopulmonary toxicity of ADCs is agent-specific rather than a class effect. Monitoring intensity, diagnostic thresholds, and management pathways must be tailored to the individual drug, regimen, indication, dose, patient comorbidity, and prior therapy. Close collaboration among oncology, radiology, pulmonology, and cardio-oncology is essential to preserve both treatment efficacy and patient safety.<\/jats:p>","DOI":"10.3390\/medicina62091664","type":"journal-article","created":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T02:08:58Z","timestamp":1788142138000},"page":"1664","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Interstitial Lung Disease and Cardiotoxicity Associated with Trastuzumab Deruxtecan, Sacituzumab Govitecan, and Trastuzumab Emtansine: A Narrative Review"],"prefix":"10.3390","volume":"62","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-5414-4108","authenticated-orcid":false,"given":"Raul","family":"Tirinescu","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, M Hospital, 10\u201312 Witting Street, 010903 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6025-5998","authenticated-orcid":false,"given":"Ana-Maria","family":"Pah","sequence":"additional","affiliation":[{"name":"Department of Cardiology, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy of Timi\u0219oara, Eftimie Murgu Square 2, 300041 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adina","family":"Tirinescu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, M Hospital, 10\u201312 Witting Street, 010903 Bucharest, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4951-1702","authenticated-orcid":false,"given":"Diana-Maria","family":"Mateescu","sequence":"additional","affiliation":[{"name":"Department of Infectious Diseases, Clinical Hospital CF Timi\u0219oara, 1 G\u0103rii Street, 300166 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3896-9599","authenticated-orcid":false,"given":"Camelia-Oana","family":"Muresan","sequence":"additional","affiliation":[{"name":"Institute of Legal Medicine Timi\u0219oara, 1A Cire\u0219ului Street, 300610 Timi\u0219oara, Romania"},{"name":"Ethics and Human Identification Research Center, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy of Timi\u0219oara, Eftimie Murgu Square 2, 300041 Timi\u0219oara, Romania"},{"name":"Discipline of Forensic Medicine, Bioethics, Deontology, and Medical Law, Department of Neuroscience, \u201cVictor Babe\u0219\u201d University of Medicine and Pharmacy of Timi\u0219oara, Eftimie Murgu Square 2, 300041 Timi\u0219oara, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,8,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1146\/annurev-med-050311-201823","article-title":"Antibody-drug conjugates in cancer therapy","volume":"64","author":"Sievers","year":"2013","journal-title":"Annu. Rev. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1038\/s41571-021-00470-8","article-title":"Unlocking the potential of antibody-drug conjugates for cancer therapy","volume":"18","author":"Drago","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_3","first-page":"165","article-title":"Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies","volume":"72","author":"Tarantino","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/cas.12966","article-title":"Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody\u2013drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity","volume":"107","author":"Ogitani","year":"2016","journal-title":"Cancer Sci."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1080\/14712598.2020.1757067","article-title":"Sacituzumab govitecan, a novel, third-generation, antibody-drug conjugate (ADC) for cancer therapy","volume":"20","author":"Goldenberg","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_7","unstructured":"U.S. Food and Drug Administration (2026, August 24). ENHERTU (fam-trastuzumab deruxtecan-nxki): Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/761139s039lbl.pdf."},{"key":"ref_8","unstructured":"U.S. Food and Drug Administration (2026, August 24). KADCYLA (ado-trastuzumab emtansine): Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/125427s125lbl.pdf."},{"key":"ref_9","unstructured":"U.S. Food and Drug Administration (2026, August 24). TRODELVY (sacituzumab govitecan-hziy): Prescribing Information, Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2026\/761115s064lbl.pdf."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41523-022-00467-1","article-title":"Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"8","author":"Rugo","year":"2022","journal-title":"npj Breast Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Liu, W., Du, Y., Guo, X., Ye, H., and Liu, J. (2023). Post-marketing safety surveillance of sacituzumab govitecan: An observational pharmacovigilance study leveraging the FAERS database. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1283247"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Gui, X., Zhao, J., Ding, L., Chai, J., Lai, H., Cai, Y., Luo, S., Zeng, Y., Wu, W., and Chen, H. (2023). Assessing real-world safety concerns of sacituzumab govitecan: A disproportionality analysis using spontaneous reports in the FDA Adverse Event Reporting System. Front. Oncol., 13.","DOI":"10.3389\/fonc.2023.1276976"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13256-025-05820-z","article-title":"Interstitial pneumonitis related to sacituzumab govitecan in a patient with metastatic triple-negative breast cancer: A case report","volume":"20","author":"Lin","year":"2026","journal-title":"J. Med. Case Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.ejca.2019.11.023","article-title":"Trastuzumab emtansine (T-DM1)-associated cardiotoxicity: Pooled analysis in advanced HER2-positive breast cancer","volume":"126","author":"Ameye","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"03000605211053755","DOI":"10.1177\/03000605211053755","article-title":"Cardiotoxicity of trastuzumab emtansine (T-DM1): A single-center experience","volume":"49","author":"Acibuca","year":"2021","journal-title":"J. Int. Med. Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1007\/s11912-021-01114-x","article-title":"Cardiovascular toxicity of novel HER2-targeted therapies in the treatment of breast cancer","volume":"23","author":"Dent","year":"2021","journal-title":"Curr. Oncol. Rep."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e2540336","DOI":"10.1001\/jamanetworkopen.2025.40336","article-title":"Cardiotoxic effects of antibody drug conjugates vs standard chemotherapy in erbb2-positive advanced breast cancer: A systematic review and meta-analysis","volume":"8","author":"Seth","year":"2025","journal-title":"JAMA Netw. Open"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"100554","DOI":"10.1016\/j.esmoop.2022.100554","article-title":"Pooled analysis of drug-related interstitial lung disease and\/or pneumonitis in nine trastuzumab deruxtecan monotherapy studies","volume":"7","author":"Powell","year":"2022","journal-title":"ESMO Open"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"102378","DOI":"10.1016\/j.ctrv.2022.102378","article-title":"Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease\/pneumonitis\u2014Focus on proactive monitoring, diagnosis, and management","volume":"106","author":"Swain","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"102043","DOI":"10.1016\/j.esmoop.2023.102043","article-title":"Multidisciplinary clinical guidelines in proactive monitoring, early diagnosis, and effective management of trastuzumab deruxtecan (T-DXd)-induced interstitial lung disease (ILD) in breast cancer patients","volume":"8","author":"Wekking","year":"2023","journal-title":"ESMO Open"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s40264-023-01328-x","article-title":"Clinical guidance on the monitoring and management of trastuzumab deruxtecan (T-DXd)-related adverse events: Insights from an Asia-Pacific multidisciplinary panel","volume":"46","author":"Chiu","year":"2023","journal-title":"Drug Saf."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1158\/1078-0432.CCR-14-3321","article-title":"First-in-human trial of a novel anti-Trop-2 antibody-SN-38 conjugate, sacituzumab govitecan, for the treatment of diverse metastatic solid tumors","volume":"21","author":"Starodub","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/cpt.3098","article-title":"Postmarketing safety of sacituzumab govitecan: A pharmacovigilance study based on the FDA Adverse Event Reporting System","volume":"115","author":"Li","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1002\/onco.13878","article-title":"Sacituzumab govitecan for metastatic triple-negative breast cancer: Clinical overview and management of potential toxicities","volume":"26","author":"Spring","year":"2021","journal-title":"Oncologist"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.chest.2020.11.027","article-title":"Chest CT diagnosis and clinical management of drug-related pneumonitis in patients receiving molecular targeting agents and immune checkpoint inhibitors: A position paper from the Fleischner Society","volume":"159","author":"Johkoh","year":"2021","journal-title":"Chest"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Skeoch, S., Weatherley, N., Swift, A.J., Oldroyd, A., Johns, C., Hayton, C., Giollo, A., Wild, J.M., Waterton, J.C., and Buch, M. (2018). Drug-induced interstitial lung disease: A systematic review. J. Clin. Med., 7.","DOI":"10.3390\/jcm7100356"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa1914510","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive breast cancer","volume":"382","author":"Modi","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.annonc.2023.12.001","article-title":"Trastuzumab deruxtecan in previously treated patients with HER2-positive metastatic breast cancer: Updated survival results from a phase II trial (DESTINY-Breast01)","volume":"35","author":"Saura","year":"2024","journal-title":"Ann. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer","volume":"386","author":"Kim","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0140-6736(22)02420-5","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: Updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial","volume":"401","author":"Hurvitz","year":"2023","journal-title":"Lancet"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1038\/s41591-024-03021-7","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: Long-term survival analysis of the DESTINY-Breast03 trial","volume":"30","author":"Hurvitz","year":"2024","journal-title":"Nat. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"oyaf396","DOI":"10.1093\/oncolo\/oyaf396","article-title":"Characterization of the safety profile of trastuzumab deruxtecan by dose: A pooled analysis across DESTINY studies","volume":"31","author":"Park","year":"2026","journal-title":"Oncologist"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"101613","DOI":"10.1016\/j.esmoop.2023.101613","article-title":"Incidence of interstitial lung disease and cardiotoxicity with trastuzumab deruxtecan in breast cancer patients: A systematic review and single-arm meta-analysis","volume":"8","author":"Soares","year":"2023","journal-title":"ESMO Open"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1007\/s12094-024-03383-x","article-title":"Safety profile of trastuzumab deruxtecan in advanced breast cancer: Expert opinion on adverse event management","volume":"26","author":"Ciruelos","year":"2024","journal-title":"Clin. Transl. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1007\/s12282-025-01814-3","article-title":"Real-world analysis of interstitial lung disease\/pneumonitis in Japanese patients with breast cancer receiving trastuzumab deruxtecan","volume":"33","author":"Tsurutani","year":"2026","journal-title":"Breast Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/s41523-026-00936-x","article-title":"Comparison of T-DXd-associated pulmonary toxicity in real-world settings and clinical trials","volume":"12","author":"Udovica","year":"2026","journal-title":"npj Breast Cancer"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.annonc.2025.07.015","article-title":"Pooled analysis of trastuzumab deruxtecan retreatment after recovery from grade 1 interstitial lung disease\/pneumonitis","volume":"36","author":"Rugo","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab emtansine for residual invasive HER2-positive breast cancer","volume":"380","author":"Huang","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S1470-2045(14)70178-0","article-title":"Trastuzumab emtansine versus treatment of physician\u2019s choice for pretreated HER2-positive advanced breast cancer (TH3RESA): A randomised, open-label, phase 3 trial","volume":"15","author":"Krop","year":"2014","journal-title":"Lancet Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1798","DOI":"10.1177\/1078155218813716","article-title":"Interstitial pneumonitis associated with trastuzumab emtansine","volume":"25","author":"Alkan","year":"2019","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1177\/10781552211066073","article-title":"Pneumonitis associated with trastuzumab emtansine in a patient with metastatic breast cancer","volume":"28","author":"Araz","year":"2022","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10549-020-05754-8","article-title":"Incidence of pneumonitis\/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer","volume":"183","author":"Hackshaw","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1200\/JCO.20.03489","article-title":"TROPHY-U-01: A phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors","volume":"39","author":"Tagawa","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.1093\/eurheartj\/ehac244","article-title":"2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO), and the International Cardio-Oncology Society (IC-OS)","volume":"43","author":"Lyon","year":"2022","journal-title":"Eur. Heart J."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.annonc.2019.10.023","article-title":"Management of cardiac disease in cancer patients throughout oncological treatment: ESMO consensus recommendations","volume":"31","author":"Curigliano","year":"2020","journal-title":"Ann. Oncol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","article-title":"Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: A position statement and new risk-assessment tools from the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"ref_50","unstructured":"National Cancer Institute (2026, August 24). Common Terminology Criteria for Adverse Events (CTCAE), Available online: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.jaccao.2026.07.006","article-title":"Cardiovascular toxicity of antibody-drug conjugates in breast cancer: Current evidence and evolving considerations: JACC: CardioOncology primer","volume":"8","author":"Moore","year":"2026","journal-title":"JACC CardioOncol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1056\/NEJMoa2508668","article-title":"Trastuzumab deruxtecan plus pertuzumab for HER2-positive metastatic breast cancer","volume":"394","author":"Tolaney","year":"2026","journal-title":"N. Engl. J. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): A randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Rugo","year":"2023","journal-title":"Lancet"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMoa1814213","article-title":"Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer","volume":"380","author":"Bardia","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"478","DOI":"10.5543\/tkda.2022.22359","article-title":"Anthracycline chemotherapy-induced electro-mechanical changes: Strain echocardiography combined with repolarization parameters on electrocardiography to predict early cardiotoxicity","volume":"50","author":"Kemal","year":"2022","journal-title":"Turk Kardiyol. Dern. Ars."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"476","DOI":"10.5543\/tkda.2022.22610","article-title":"How to see cardiotoxicity beyond imaging in 2022","volume":"50","author":"Merke","year":"2022","journal-title":"Turk Kardiyol. Dern. Ars."}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/9\/1664\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T03:26:23Z","timestamp":1788146783000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/9\/1664"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,30]]},"references-count":58,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["medicina62091664"],"URL":"https:\/\/doi.org\/10.3390\/medicina62091664","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,30]]}}}